Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00182052 · ClinicalTrials.gov registry record · Phase 3
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00182052: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00182052 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00182052, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.
Interventions
- OTHER Placebo
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2000-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00182052
The ClinicalTrials.gov registry entry for NCT00182052 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00182052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00182052 about?
NCT00182052 is a clinical study titled "Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer". The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.
What is the current status of trial NCT00182052?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2000-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00182052?
The interventions under investigation include: Placebo (OTHER), Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00182052?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.